Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG intravesical instillation for prevention of recurrence after surgery in intermediate- and high-risk non-muscle-invasive bladder cancer
CTR20150840Phase 4Active
- Sponsor
- Chengdu Institute of Biological Products
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), Bladder cancer in situ (CIS), sponsored by Chengdu Institute of Biological Products. Started Jul 2015; status: active.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on CTR20150840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150840.